Abstract
One of the most common pathologies in the structure of digestive diseases is gastroesophageal reflux disease (GERD), which is associated with low life quality of patients, while in insufficient disease control — with an increased risk of Barrett's esophagus and, as a consequence, adenocarcinoma. In accordance with the relevant consensus papers, in particular, the Lyon Consensus, a key factor in the GERD pathogenesis is a persistent disorder of the upper digestive tract motility with the formation of pathological gastric reflux (in some cases, duodenum) contents into the esophagus, which determines the expediency of including prokinetics in the treatment regimen of the disease. This article provides information about the main risk factors and mechanisms of the pathological reflux in GERD, the frequency and duration of which determine the risk and progression of the disease. Special attention is paid to the modern methods for the correction of esophageal and gastric motor disorders, including the role of prokinetics in the patient's therapy. KEYWORDS: prokinetics, gastroesophageal reflux disease, functional dyspepsia, itopride hydrochloride. FOR CITATION: Livzan M.A., Bordin D.S., Gaus O.V., Lisovsky M.A. Prokinetics: the role in the therapy of a patient with GERD. Russian Medical Inquiry. 2023;7(5):283–291 (in Russ.). DOI: 10.32364/2587-6821-2023-7-5-6.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
